Saltar a la navegació principal
Saltar a la cerca
Vés al contingut principal
Ordenar per
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
76%
Diffuse Large B-cell Lymphoma (DLBCL)
72%
Reduced-intensity Conditioning
63%
Overall Survival
56%
Chimeric Antigen Receptor T Cells (CAR-T)
45%
Graft-versus-host Disease (GvHD)
33%
Rituximab
33%
Fludarabine
31%
Lymphoma Patients
29%
Lymphoma
28%
B-cell Lymphoma
26%
Progression-free Survival
23%
International Prognostic Index
22%
R-CHOP
21%
Chronic Lymphocytic Leukemia
21%
Chimeric Antigen Receptor T-cell Therapy
20%
Non-Hodgkin Lymphoma
20%
Non-relapse Mortality
19%
Confidence Interval
19%
High Risk
17%
Allo-RIC
17%
Relapsed or Refractory
16%
Follicular Lymphoma
16%
Multivariate Analysis
16%
Tumor
15%
Outcome Prediction
15%
T Memory Stem Cells
15%
Tisagenlecleucel
15%
Inolimomab
15%
Pretransplant
14%
Natural Killer Cells
14%
Iron Overload
14%
Steroid-refractory Acute Graft-versus-host Disease
14%
Refractory Acute Graft-versus-host Disease
14%
Infection-related Mortality
14%
CD19+
14%
B-CLL
14%
Invariant Natural Killer T Cells
14%
Prognostic Score
14%
Phase II Study
14%
Aggressive B-cell Lymphoma
14%
Cutaneous T-cell Lymphoma
14%
Hematopoietic Stem Cell Transplantation
13%
Interleukin-15 (IL-15)
13%
Chronic Lymphocytic Leukemia Cells
12%
Steroid-refractory
12%
Melphalan
12%
High-risk Population
12%
Hazard Ratio
11%
Lymphoma Cells
11%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
56%
Reduced Intensity Conditioning
49%
Overall Survival
48%
Allogeneic Stem Cell Transplantation
44%
B-Cell Lymphoma
32%
Diseases
26%
Rituximab
25%
International Prognostic Index
22%
Non-Hodgkin Lymphoma
22%
Chimeric Antigen Receptor T-Cell
22%
Progression Free Survival
22%
Acute Graft Versus Host Disease
21%
B-Cell Chronic Lymphocytic Leukemia
21%
Conditioning
17%
Follicular Lymphoma
17%
Chimeric Antigen Receptor
16%
Fludarabine
16%
B Cell
16%
Hematopoietic Cell
15%
Infection
15%
High Risk Population
15%
Cell Transplantation
14%
Multivariate Analysis
14%
T Cell
14%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
14%
Iron Overload
14%
Natural Killer Cell
14%
Cutaneous T Cell Lymphoma
14%
Allogeneic Hematopoietic Stem Cell Transplantation
12%
Hazard Ratio
11%
Melphalan
11%
Chimeric Antigen Receptor T-Cell Immunotherapy
10%
Aggressive Lymphoma
10%
Graft Versus Host Reaction
10%
Intermediate Risk Population
10%
Autologous Stem Cell Transplantation
9%
Epstein Barr Virus
9%
Chronic Graft Versus Host Disease
9%
Tumor Cell
9%
Neoplasm
8%
Cyclosporine
8%
Immunohistochemistry
8%
Comorbidity
8%
Inolimomab
8%
Fluorescence in Situ Hybridization
8%
Hematopoietic Stem Cell Transplantation
8%
Hematologic Malignancy
7%
Lymphoma Cell
7%
Hematology
7%
Prospective Study
7%
Immunology and Microbiology
B Cell
100%
Conditioning
50%
Overall Survival
35%
Chimeric Antigen Receptor T-Cell
35%
Allogeneic Stem Cell Transplantation
29%
Infection
25%
T Cell
25%
Rituximab
24%
Chimeric Antigen Receptor
22%
Acute Graft Versus Host Disease
21%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
21%
Myeloid
16%
Natural Killer T Cell
14%
Natural Killer Cell
14%
Stem Cell Transplantation
14%
CD19
12%
Interleukin 15
12%
Lymphoma Cell
11%
Graft-Versus-Host Disease
9%
Ciclosporin
9%
Progression Free Survival
9%
BCL6
9%
Hematopoietic Cell
8%
Tumor Cell
8%
Epstein Barr Virus
8%
Comorbidity
8%
Inolimomab
8%
Respiratory Virus
8%
Cell Transplantation
7%
Viral Disease
7%
Dendritic Cell
7%
High Risk Population
7%
Adoptive Immunotherapy
7%
Cell Mediated Cytotoxicity
7%
T Lymphocyte Antibody
7%
CD47
7%
Autophagy
7%
CpG Oligodeoxynucleotide
7%
Lung Function
7%
Chronic Lymphoproliferative Disorder
7%
Phagocytosis
7%
CD34
7%
Isoetarine
7%
Intermediate Risk Population
7%
Lower Respiratory Tract
7%
Protein Expression
7%
CD28
7%
Autologous Peripheral Blood Stem Cell Transplantation
7%
Peripheral Nervous System
7%
Tyrosine
7%
